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Analysis of ﬁnite dose dermal absorption data: Implications for
dermal exposure assessment
H. Frederick Frasch1, G. Scott Dotson2, Annette L. Bunge3, Chen-Peng Chen4, John W. Cherrie5, Gerald B. Kasting6,
John C. Kissel7, Jennifer Sahmel8, Sean Semple9 and Simon Wilkinson10
A common dermal exposure assessment strategy estimates the systemic uptake of chemical in contact with skin using the ﬁxed
fractional absorption approach: the dermal absorbed dose is estimated as the product of exposure and the fraction of applied
chemical that is absorbed, assumed constant for a given chemical. Despite the prominence of this approach there is little guidance
regarding the evaluation of experiments from which fractional absorption data are measured. An analysis of these experiments is
presented herein, and limitations to the ﬁxed fractional absorption approach are discussed. The analysis provides a set of simple
algebraic expressions that may be used in the evaluation of ﬁnite dose dermal absorption experiments, affording a more data-
driven approach to dermal exposure assessment. Case studies are presented that demonstrate the application of these tools to
the assessment of dermal absorption data.
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INTRODUCTION
The potential for adverse systemic health effects resulting
from dermal contact with a chemical is broadly recognized. In
situations where dermal contact may contribute signiﬁcantly to the
total body burden, assessment of the systemic uptake of
the chemical following skin contact allows for greater accuracy in
the estimation of total absorbed dose, hence, a more comprehen-
sive understanding of the risks of systemic toxicity. Therefore,
it is incumbent upon the risk assessor to consider the dermal
absorption potential of a chemical. This in turn requires a reasonable
estimate of the dermal absorbed dose, that is, the amount of
chemical that is systemically absorbed following contact with skin.
A common strategy1 practiced in dermal exposure assessment
estimates the systemic uptake of chemical by the dermal route
using the ﬁxed fractional absorption approach, in which the
dermal-absorbed dose is related to some measure of exposure
times the fraction of applied chemical that is absorbed. As an
example, in the US EPA Standard Operating Procedures for
Residential Pesticide Exposure Assessment,2 the dermal absorbed
dose is calculated as:
D¼ E  AF
BW
ð1Þ
where D is the absorbed dose (mg/kg/day), E is the exposure
(mg/day), BW is body weight (kg), and AF is the fractional
absorption factor. This factor—or its equivalent expressed
as a percent absorption—is typically an empirical quantity
that is assumed to be a ﬁxed value speciﬁc to a given chemical
regardless of exposure conditions. The fractional absorption factor
is commonly determined from ﬁnite dose in vitro or in vivo dermal
absorption studies. In these experiments, at the end of a speciﬁed
exposure duration, the dermal-absorbed dose is measured and
the fractional absorption factor is calculated as the dermal-
absorbed dose divided by the applied load.
The fractional absorption approach has been advocated by
regulatory and advisory agencies in North America and Europe. In
the United States, the EPA guidance for Superfund remediation3
as well as the Ofﬁce of Pesticide Programs,2,4 adopt this approach.
Additionally, the US Army,5,6 the Department of Homeland
Security,7 and the National Institute for Occupational Safety and
Health8 have incorporated fractional absorption in dermal risk
assessment strategies. In Europe, the European Commission’s
technical guidance for risk assessment9 emphasizes the primacy of
fractional absorption for dermal risk assessment. The EC guidance
document on dermal absorption10 provides a process for setting
dermal absorption percentages using default values or, preferably,
values determined experimentally.
There are two main advantages of the fractional absorption
approach to estimating dermal absorption. First, the ﬁnite dose
experiment can represent a good model for realistic environ-
mental and occupational exposure scenarios. In-use conditions,
including the use of vehicle, expected dose loading, and exposure
duration can be manipulated to mimic realistic exposures.
The approach is also appealing in its simplicity. The fractional
absorption factor is readily determined from dermal absorption
experiments, and this factor is easily slotted into simple algebraic
expressions such as Eq. (1) to derive the total dermal-absorbed
dose from a given exposure.
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However, this apparent simplicity is belied by complicating
factors. It has been observed that an inverse relationship often
exists between dermal loading and fractional absorption.11–13 As
the loading increases, the fraction of chemical that is absorbed
diminishes. Thus, the fractional absorption factor is not a constant
for a given chemical, and it is typically highest for low dermal
loads that are characteristic of environmental and occupational
exposures. For dermal absorption testing of a quality sufﬁcient for
regulatory submission, a range of loads are often required to be
investigated to span the range of expected exposures.14 However,
peer review reports in the open literature typically cover a narrow
range or just one load. Experiments at low loads present technical
complications for the investigator.11,15 The uniform application
of a thin homogeneous layer of the chemical of interest is
challenging and the evaluation of absorbed dose under low
loading may stress the limits of chemical detection (The term ‘‘low
loads’’ is somewhat ambiguous, but its meaning will become
clearer through the information presented in this manuscript.).
The OECD Guideline for the Testing of Chemicals16 recommends
a load of 1–5mg/cm2 for solids and up to 10 ml/cm2 for liquids
for applications that mimic human exposure, with considera-
tions for using the appropriate vehicle, for example, neat,
diluted, or formulated material containing the test substance.
This recommendation does not account for differences in dermal
absorption rates. These loads may realistically approximate
the inﬁnite dose regime for poorly absorbed materials,
whereas those that are more readily absorbed may exhibit
absorption proﬁles that are more characteristic of a ﬁnite dose
application.
Other complicating factors are related to the disposition of the
applied load. For example, a volatile chemical will both penetrate
the skin and evaporate from the skin’s surface. Evaporation will
diminish the dermal absorbed amount, but it is not evident how
to account in any quantitatively meaningful manner for the
competing kinetic processes of absorption and evaporation.
The exposure duration, or the time during which the skin remains
in contact with the chemical, is clearly a factor in determining the
absorbed amount and, hence, the fractional absorption factor. An
8-h exposure might be most relevant for occupational exposures,
but low-level environmental exposures, for example, from indoor
air contaminants, may persist indeﬁnitely. For the experimental
design and evaluation of ﬁnite dose dermal absorption data,
it is therefore important to consider the relationship between
the dermal absorption kinetics of a given compound and the
exposure duration, in order to evaluate whether a calculated
fractional absorption represents a steady state or if additional
absorption would be expected from a longer exposure
duration.
Despite the prominence of the fractional absorption approach
in dermal exposure assessment, there is little guidance on the
proper evaluation of dermal exposure and absorption data
derived from experimental observations. The purpose of this
paper is to present a systematic approach to the evaluation of
ﬁnite dose in vitro dermal absorption experiments. Limitations of
the ﬁxed fractional absorption approach are presented and
analyzed. The order of presentation is not necessarily a function
of their importance; rather for a given set of experimental
conditions, one or more may represent important considerations.
We present a quantitative framework for the analysis of ﬁnite dose
dermal absorption data that can aid in the evaluation of the
potential of a chemical to be dermally absorbed and contribute to
the systemic dose. The objective is to provide those tasked with
evaluating dermal absorption data with a sensible, data-driven
framework for dermal exposure assessment. Another goal is
to lay the framework for researchers to use in the future when
designing, conducting, and interpreting dermal absorption
studies. More detailed theoretical analyses of ﬁnite dose
absorption kinetics may be found elsewhere.17–20
LIMITATIONS OF THE FIXED FRACTIONAL ABSORPTION
APPROACH FOR ASSESSING SYSTEMIC TOXICITY FROM
DERMAL EXPOSURE
Loading Affects Fraction Absorbed
Loading conditions can have enormous effects on fractional or
percent absorption.13 Figure 1 presents a simpliﬁed case to
elucidate the effect of loading on measured percent absorbed.
This simple illustration demonstrates the crucial effect of loading
on the measured result when absorption is reported solely as the
fraction or percent of the applied amount. The example on the
right is a case where load depletion is small relative to the applied
load. This condition can readily be extrapolated to the case of an
inﬁnite load, whereby the percent absorbed must be practically
zero. Thus, absorbed amount may range from zero to 100% for
the same chemical, depending on the applied load. There are
several reasons why 100% absorption may not be achieved in a
practical setting. Chemical may bind to skin components or it
may be removed from the skin by volatilization, debridement,
sweating, or washing. This simple illustration, nevertheless,
demonstrates that the use of a speciﬁed ﬁxed cutoff value
to evaluate the dermal absorption potential of a chemical seems
unwarranted.
Given this, is it possible to draw any conclusions regarding the
absorption potential of a chemical based on the knowledge of
Figure 1. Illustration of how applied load affects percent that is
absorbed. (a) Three examples of different loads (1, 4, and 10 units) of
a given chemical on skin. (b) As long as absorption has not depleted
the amount of chemical on the skin too much, flux of the chemical is
the same under all conditions. (c) If the experimental duration
is such that one load unit penetrates the skin into receptor fluid
then on the left, 100% of the load is absorbed; in the middle,
the value is 25%; and on the right it is 10%.
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the fraction of applied ﬁnite dose that is absorbed? Kissel13
proposed a dimensionless ratio, Nderm, that may prove useful in
the evaluation and interpretation of ﬁnite dose experiments.
The dermal number quantiﬁes the ratio of applied load and
absorbable amount:
Nderm¼ experimental loadsteady-state flux experimental duration ð2Þ
Experimental load is the mass of chemical applied per unit area
of exposed skin, and steady-state ﬂux (Jss) is the steady-state
absorption rate (mass/area/time) for the chemical at a speciﬁed
dilution. Jss can be experimentally determined using inﬁnite doses
of chemical at the dilution of interest as donor. In the absence of
experimental knowledge of Jss, it may be estimated by using any
number of theoretical models that predict the steady-state
permeability coefﬁcient (kp,v, length/time) of a compound from
a given vehicle (typically, water), along with the knowledge of the
concentration (Cv, mass/volume) of the compound in that vehicle
(providing the compound or other components in the vehicle do
not signiﬁcantly alter the skin’s barrier):
Jss¼ kp;v  Cv ð3Þ
We note that this deﬁnition of Nderm (Eq. (2)) differs from that of
Kissel13 in that Kissel uses maximum ﬂux in place of steady-state
ﬂux. Maximum ﬂux represents the steady-state ﬂux from
neat chemical or saturated solution, and its use is appropriate
for such donors. Because in practice diluted solutions of chemical
are often studied, Nderm as deﬁned here is more generally
applicable.
The distinction is made between maximum ﬂux and peak ﬂux.
The latter is deﬁned as the highest ﬂux achieved from a given
dose. Any in vitro diffusion experiment will exhibit a peak ﬂux, the
magnitude of which depends on donor concentration and
loading. As loading increases, so too will peak ﬂux until a value
is reached, which corresponds to the highest ﬂux obtainable from
a given donor. If the donor is a neat chemical or a saturated
solution, the peak ﬂux will equal maximum ﬂux (once again,
provided the chemical or other components in the vehicle do not
signiﬁcantly alter the skin’s barrier).
High values of Nderm signify an experiment that is ﬂux limited;
that is, one where there is ample load that is not signiﬁcantly
depleted through the time course of the experiment. Under this
condition, % absorption varies inversely with load. In the
simpliﬁed case described in Figure 1, a load of 10 units resulted
in an absorption of 10% of the applied load. Consider a load of
100 units. Under the described conditions, only 1% of the applied
load will be absorbed; for a load of 1000 units, 0.1% is absorbed;
and so on. This inverse relationship between dermal load and
relative dermal absorption has been noted in recent reviews of
the literature,11–13 suggesting that a substantial proportion of
ﬁnite dose experiments are performed in the high Nderm regime.
Generally, high values of Nderm are not representative of the low
loads typically encountered in occupational or environmental
exposures and the reported % absorption under these conditions
is not a useful indicator of the potential of a chemical to be
dermally absorbed.
If the entire time course of dermal absorption is provided by the
report, then important information can be obtained from
experiments with high Nderm values. This regime allows the most
reliable estimates of maximum ﬂux and lag time. Because load
depletion does not limit ﬂux, it is likely that the experimental ﬂux
under high Nderm conditions approaches Jmax of the chemical, if
the chemical is applied neat or in a saturated solution. An
exception to this rule may occur if a solid chemical is applied
without a solvent, particularly, if it is coarsely divided or highly
crystalline; in this case, absorption may become dissolution
limited.
A low value of Nderm signiﬁes a delivery-limited state, where
signiﬁcant load depletion is expected to occur. This condition
is a more proper application of the term ‘‘ﬁnite dose’’ and the
measured peak ﬂux under this condition will be less than the
maximum steady-state ﬂux possible for the speciﬁed donor, owing
to depletion of the load.
Figure 2 displays experimental data that illustrate how Nderm
affects both the percent of applied load and the total amount
that are absorbed. Previously published17 in vitro split thickness
human cadaver skin absorption data of the model compound
vanillylnonanamide, a synthetic capsaicin, have been recast to
display percent absorption and total absorbed amount as
functions of the parameter Nderm. For an experimental duration
of 72 h and maximum ﬂux (measured) of 2 mg/cm2/h, the load
equivalent to an Nderm of 1 was 144 mg/cm
2. For small loads
(Ndermo0.1) of this particular compound, absorption plateaus at
B40–50% of the applied dose, whereas for larger loads
(Nderm410), absorption is less than 10%. On the other hand, as
dose is increased the total amount of the compound that is
absorbed also increases, as expected. We emphasize that
absorption here refers to the amount of chemical that has
passed through the skin and into the receptor compartment,
and does not include the amount deposited within the skin.
This may contribute to the observation that absorption does
not approach 100% at low loads. Another possibility is that
the experimental duration was not long enough to observe
100% absorption.
It is difﬁcult to assign a precise cutoff value of Nderm to
distinguish between ﬂux-limited and delivery-limited absorption.
A complicating issue is the fact that the experimental duration
(a variable in the denominator of Eq. (2)) may have been selected
without consideration for the kinetics of the absorption process
for the particular chemical investigated. For the data displayed in
Figure 2, ﬂux limitation does not appear to be reached at the
maximum Nderm studied (B30). There exists a near linear
relationship between dermal loading and total absorbed amount
for NdermB1 and greater, but a plateau in total absorbed amount
is not reached.
Case study 1 provides an example from the literature of a failure
to consider the effect of loading on fractional absorption and
demonstrates how a critical analysis, as advocated herein and
by Kissel,13 may be applied in the evaluation of ﬁnite dose
absorption data.
Figure 2. Percent absorption and total amount absorbed for the
chemical vanillylnonanamide. Previously published in vitro human
skin absorption data12 has been recast as a function of the
dimensionless dermal number Nderm, which quantifies the ratio of
applied load and dermal absorption. Data demonstrate that %
absorption diminishes with increasing load. Absorption does not
include the skin depot amount.
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Case study 1: Pentabromodiphenyl ether
The European Union has published a risk assessment for pentabromo-
diphenyl ether.21 In that document, dermal exposure was evaluated
using a ﬁxed fractional absorption approach. In the worker exposure
scenario, delivery of 0.1mg/cm2/day to exposed skin was predicted
using the Estimation and Assessment of Substance Exposure model. Of
this amount, up to 60% was assumed to be absorbed based on
experimental results obtained for PCBs in guinea pigs.22 The ﬂux
required to sustain the equivalent systemic dose can be calculated as:
0:1mg
cm2 day 1000mgmg  1day24 h 60 % ¼ 2:5mg=cm2=h
Roper et al.23 conducted in vitro (human cadaver skin) absorption
experiments using 14C-labeled tetrabromodiphenyl ether as a surrogate
for pentabromodiphenyl ether. A purpose of the study was explicitly
stated to be ‘‘to challenge the default value of 60%’’. Observed uptake
(skin plus receptor ﬂuid) was 3.13±1.15% (n¼ 10) and the absorbed
dose (receptor ﬂuid) was 1.94±0.98% over a 24-h exposure. Because
both fractions are much less than 60%, Roper et al. concluded that the
ECB risk assessment was unduly conservative. However, in the Roper
et al. experiments, the applied load was 10,000mg/cm2. The
corresponding average systemic ﬂux can be calculated as at least:
10;000mg
cm2  124h1:94 % ¼ 8:1mg=cm2=h
Therefore, the experimentally observed ﬂux was actually over three
times greater than that implicitly assumed in the ‘‘worst-case’’ ECB risk
assessment. The comparatively low experimental absorption efﬁciency is
simply an artifact of the 100 greater surface load used experimentally
than assumed in the risk assessment. If this measured ﬂux is the
maximum ﬂux for this chemical, a reasonable assumption given that the
authors applied neat compound and a steady-state appeared to have
been reached within 4–6 h, then
Nderm¼ 10;000mg=cm
2
8:1mg=cm2=h24h  50;
and the experiment clearly lies within the ﬂux-limited regime.
Additional experimental details, including the use of ethanol as the
receptor ﬂuid, might have been used to argue that the observed results
were conservatively high, but Roper et al. did not do so. They simply
noted that 1.94 and 3.13% were much less than 60%, revealing failure to
consider the effect of loading on fractional absorption.
Evaporation or Sublimation of Volatile Compounds Affects
Fraction Absorbed
Volatility of the test material is another variable that requires
consideration. Fractional absorption of a volatile compound will
depend not only on the experimental load, but also on the rate of
evaporation compared with the rate of absorption. A highly
volatile compound will evaporate from an unoccluded donor and
will not be available for dermal absorption. Although small doses
of a volatile compound may well represent a reasonable in-use
exposure to splashes of chemical, and as such does yield useful
data, this scenario may not provide much information regarding
the permeability potential of the compound.
The Nderm parameter described above (Eq. (2)) does not take
into consideration the volatility of the chemical. Therefore, in
analogy with Nderm, we propose a dimensionless number that
quantiﬁes the balance between applied load and depletion
through evaporation. The evaporation number is deﬁned as:
Nevap¼ Experimental loadSteady-state evaporation flux exposure duration
ð4Þ
Units for load, ﬂux, and duration are the same as those
for Nderm. Measured values of evaporation ﬂux are unlikely to
be available for most chemicals of interest. In these cases,
approximations can be made using empirical or semi-theoretically
based models. An example is the US EPA equation for estimating
evaporation ﬂux from the surface of chemical spills.24 This
equation has also been applied to estimate evaporation from
the donor compartment of diffusion cells25–27 and is presented
here in the Appendix.
High values of Nevap signify the ﬂux-limited condition in which
there is no signiﬁcant load depletion through evaporation. Low
values of Nevap suggest a delivery-limited condition, whereby
signiﬁcant evaporative losses reduce the observed ﬂux. In contrast
with low values of Nderm, the percent of applied dose that is
dermally absorbed may be quite low for low Nevap. Owing to
substantial evaporation, less chemical is available for dermal
absorption.
The dimensionless ﬂux number (Nﬂux) should prove useful in the
evaluation of dermal absorption studies using volatile chemicals.
It quantiﬁes the balance between evaporation and absorption:
Nflux¼ Steady-state dermal fluxSteady-state evaporation flux ð5Þ
Both dermal ﬂux and evaporation ﬂux should be evaluated
under the same experimental donor conditions (e.g., neat or
diluted). If both ﬂuxes represent maximum ﬂuxes, then Nﬂux is
exactly equal to the inverse of the parameter w described by
Kasting and Miller.18 Low values of Nﬂux indicate a condition
in which the measured dermal absorption will be diminished by
evaporative losses. For Nﬂux51, the permeant will largely
evaporate from the skin surface. Conversely, large values of Nﬂux
are indicative of a compound that will primarily be absorbed. The
time scale over which these competing processes occur depends
on the membrane lag time, as demonstrated by Kasting and
Miller.18 In brief, surface evaporation commences immediately
following application of the load to the skin, whereas dermal ﬂux
requires some amount of time, related to the membrane lag time,
to become established.
Another useful parameter can be used in the evaluation of ﬁnite
dose absorption data from volatile compounds. One may estimate
the time for evaporation of the applied dose to occur using the
evaporation time, deﬁned as:
tevap¼ Experimental loadSteady-state evaporation flux ð6Þ
The comparison of tevap with the exposure duration of the
applied dose is key. If tevap is much greater than the exposure
duration, the experiment is ﬂux limited. That is, there is
insigniﬁcant load depletion due to evaporation. If tevap is less
than the exposure duration, this implies a delivery-limited
condition, in which evaporation will limit the load available for
dermal absorption, and experimental ﬂux values will be reduced
by evaporation.
Figure 3 displays model-based predictions of the % of applied
dose that is absorbed and the total amount absorbed as functions
of Nderm, for a broad range of Nﬂux values. Calculations were made
using the Finite Dose Skin Permeation Calculator,28 which solves
for the disposition of an applied surface load and is based on
research undertaken by Kasting’s group.17,18 These simulations are
based on a hypothetical model compound for which the vapor
pressure was arbitrarily varied to achieve the speciﬁed values of
Nﬂux. Modeled maximum ﬂux was 10.8 mg/cm
2/h and lag time was
1.33 h. The vapor pressure required to achieve an Nﬂux of 1 was
0.48 Pa at 32 1C. Simulated experimental duration was 8 h.
For Nderm less than about 10, Figure 3 shows that percent
absorbed increases with Nﬂux. Frasch showed
29 through
theoretical analysis of Kasting’s ﬁnite dose model that for low
loads, the total absorbed fraction of applied dose at inﬁnite time
after exposure may be estimated as:
AF¼ f þ 2Nflux
2þ 2Nflux ð7Þ
Here, f is the fractional thickness of the desquamating layer of the
stratum corneum; a reasonable value for f is 0.1.18 Equation (7)
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may be used to estimate fractional absorption under low-load
conditions.
Not only does % absorbed increase with Nﬂux, but so does the
total amount that is absorbed (Figure 3b). For a non-volatile
compound (Nﬂux-N), ﬂux limitation appears at NdermB1. Total
absorbed amount approaches its maximum value for NdermZ1,
indicating that absorption is approaching the regime of inﬁnite
loading. Any additional loading beyond this point is excess; it does
not contribute to absorption but does diminish the observed
percent of load that is absorbed. For a high-volatility compound
(Nﬂux¼ 0.1), this ﬂux-limited regime is not revealed until
NdermB10 (see Figure 3).
Although the data shown in Figure 3 are model based,
the models have been validated with experimental data.17,26,30
For any given compound, in vitro absorption data may not be
accurately predicted by this family of curves, but we would expect
the trends to conform to these modeled data.
Case study 2 presents an application of concepts outlined here
to the evaluation of dermal toxicity and absorption data from a
volatile compound. This study demonstrates the importance
of considering concurrent effects of both loading and evaporation
in analyzing the presented data. As suggested by the
data in Figure 3, it is important to consider both Nderm and
Nevap for volatile compounds. As a general approach, it may
be prudent to consider evaporation for cases where Nﬂux r10;
that is, where evaporation contributes 10% or more to applied
load losses.
Case study 2: 1-Bromopropane (1-BP)
Elf Atochem undertook a dermal toxicity study, in which they applied
2000mg/kg of 1-BP neat to shaved skin of rats and covered the
application area with gauze for 24 h.31 After 2 weeks, there were no
signs of dermal toxicity and the study concluded that the dermal LD50
exceeds 2000mg/kg. The American Conference of Governmental
Industrial Hygienists cited this study in their conclusion that ‘‘there is
no basis for a skin notation’’ for 1-BP.32
The maximum ﬂux of 1-BP has been measured27 at B1mg/cm2/h.
Assuming a typical rat weight of 0.25 kg and a dermal application area of
20 cm2 gives
Nderm¼ 2000mg=kg0:25 kg=20cm
2
1mg=cm2=h14 days24h=day ¼ 0:074
This low value indicates delivery limitation where signiﬁcant load
depletion is expected. Consideration of Nderm alone would indicate that
a substantial fraction of the applied dose was absorbed by the rats.
However, 1-BP is a highly volatile halogenated short-chain alkane with a
reported vapor pressure (Pvap) of 111mmHg at 20 1C.
33 The evaporation
ﬂux of this chemical can be estimated using the equations in the
Appendix. Because a typical skin surface temperature is 32 1C, Eq. (A2) is
used to estimate Pvap at this temperature. A value of 32,130 J/mol for
DHvap of 1-BP has been reported,
34 yielding an estimate of 163mmHg
for Pvap at 32 1C. Using this in Eq. (A1) with a wind speed of 0.3m/s
yields:
Jevap  600 mg=cm2=h;
tevap¼ 2000mg=kg  0:25 kg=20cm
2
600mg=cm2=h  60min=h ¼ 2:5min
Thus, the entire applied load is estimated to have evaporated within
minutes after application. Also we have
Nevap¼ 2000mg=kg0:25 kg=20cm
2
600mg=cm2=h14 days24h=day ¼ 0:0001
This low value indicates a delivery-limited state with substantial load
depletion from evaporation. The Nﬂux number differentiates which
process, absorption or evaporation, dominates:
Nflux¼ 1 mg=cm
2=h
600 mg=cm2=h
¼ 0:002
The rapid evaporation of applied 1-BP in the rat dermal toxicity study
meant that very little of the applied dose was available to penetrate the
skin. The reported low dermal toxicity of this compound could simply be
a result of its rapid evaporation. An interpretation of the dermal LD50
data based on an intrinsically low absorption rate and/or low systemic
toxicity is not supported by this study.
This analysis is supported by recent experiments comparing the human
epidermal absorption of 1-BP following ﬁnite dose and inﬁnite dose
exposures.27 The authors report minimal (o0.2%) absorption of the
applied unoccluded ﬁnite dose, despite a substantial maximum steady-
state dermal ﬂux of B1mg/cm2/h. Despite the considerable rate at
which 1-BP penetrates skin, it pales in comparison with the rate at which
it evaporates.
Experimental Duration Affects Measured % Absorbed
Another variable that needs to be considered in the evaluation of
ﬁnite dose experiments is the experimental duration in relation-
ship to the dermal absorption kinetics. The experimental duration
is a term in the expressions for both Nderm (Eq. (2)) and Nevap
(Eq. (4)), and therefore merits some discussion.
The experimental duration is generally established at the
discretion of the investigator and it may be inﬂuenced by a
number of considerations, including an attempt to mimic a
deﬁned occupational exposure duration, concern for tissue
deterioration in an in vitro setting, and convenience. For the
experimental duration to be a meaningful metric in the equations
for Nderm and Nevap, its relationship to the kinetics of the
absorption process is important. Consider a case where the ﬁnite
dose is fully depleted, through dermal absorption, evaporation, or
some combination. Any increase in experimental duration beyond
this time will result in lower values of Nderm and Nevap, but
Figure 3. Model-based data showing how % absorption (a) and total
absorbed amount (b) are modified by volatility of the compound
for selected values of Nderm. The dimensionless flux number, Nflux,
quantifies the balance between absorptive and evaporative fluxes.
Dermal absorption depends both on volatility and load. Symbols
represent calculated values; the lines are a guide to the eye.
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this decrease is misleading because the dynamic interplay of the
diffusion/evaporation process has already abated. One means of
evaluating this is to compare the experimental duration with the
diffusion lag time (tlag or t) using the time number:
Ntime¼ Experimental durationLag time for diffusion ð8Þ
The lag time is generally measured from an inﬁnite dose in vitro
permeation experiment as the time axis intercept of the
asymptote of the absorption curve; typical values range from
several minutes to several hours. Lag time measurements for the
chemical of interest may be reported in the literature or estimated
from the absorption proﬁle, if it has been presented. However,
their measurement may be problematic and there could be large
variance in the reported quantity. Lag time estimates predicted
from physico-chemical descriptors have had limited success.
If the lag time is not reported, an evaluation of whether steady-
state absorption has been achieved is possible if the entire time
course of dermal absorption is available. If a plateau in the
absorption proﬁle has not been reached by the end of the
experimental duration, one may infer that additional absorption is
to be expected over additional time.
Figure 4 presents model-based data (again, using the Finite
Dose Skin Permeation Calculator) for a hypothetical non-volatile
compound (vapor pressure¼ 0) that demonstrate the effect of
experimental duration on absorbed amount as a function of Nderm.
The same model parameters that were used to generate the data
for Figure 3 were used here as well, except that experimental
duration and applied dose were modiﬁed to achieve the speciﬁed
values of Nderm and Ntime. For small values of Nderm, 100%
absorption is possible but very long experimental durations are
required. According to the data in Figure 4, experimental
durations in excess of about 10 lag times would be required to
approach 100% absorption. Depending on the chemical of
interest, this may range from hours to days, during which time
surface removal of the chemical through sweating, washing, and
debridement will reduce absorption. For experimental durations
approximately equal to the lag time, one can expect no more than
B20% of the applied dose to be absorbed. For these short
experimental durations, most of the applied dose resides on the
skin surface and within the stratum corneum.
Note that for a given value of Nderm, the applied load increases
with Ntime for a given chemical, in accordance with Eq. (2). It is
important to keep in mind the interplay among these different
parameters when evaluating ﬁnite dose absorption data. Figure 4b
shows the total mass absorbed for the hypothetical model
chemical. This amount increases substantially with experimental
duration. For all values of Ntime, a plateau is reached at NdermZ1,
indicating ﬂux limitation, but the height of the plateau increases
for a given compound with Ntime because both total load and also
the time over which absorption is measured increase with this
parameter.
Absorption Continues After Removal of Load
If a load is applied to the skin’s surface and later removed,
chemical will continue to penetrate the skin for some time
afterward, even with 100% efﬁciency in skin residue removal.
Some chemical remains in the skin after washing. This reservoir
has a higher concentration near the surface, which drives
transport through the skin. For volatile compounds, evaporation
through the skin surface competes with this process so that post-
exposure absorption diminishes with increasing volatility. For
in vitro exposures designed to mimic a speciﬁc scenario, for
example, 8 h followed by wash to mimic workplace exposures, it is
therefore appropriate to follow permeation beyond the exposure
duration to account for absorption from the skin reservoir. This
phenomenon has been studied theoretically with some
experimental validation.20 The authors propose the following to
estimate the total mass absorbed, per unit area of exposed skin,
for a transient exposure to a non-volatile permeant:20,35
mabs¼ kp;v  Cv texpþ 2t
  ð9Þ
with kp,v the permeability coefﬁcient for the permeant in the given
vehicle, Cv the concentration in that vehicle, and texp the exposure
duration. Steady-state ﬂux may be substituted for the product
kp,vCv (Eq. (3)). Equation (9) gives the total absorption that occurs
through the duration of the exposure period, plus that which
occurs after removal of the compound from the skin surface. The
equation is valid if load depletion has not diminished absorption
before removal of the compound. Volatility of the applied
permeant will lead to evaporative losses through the skin surface
upon removal of the compound, reducing the absorbed amount.
For highly volatile compounds (say, Nevapr0.1), the following may
be used:20
mabs¼ kp;v  Cv  texp ð10Þ
Equation (9) thus represents the maximum possible absorbed
amount and can be used as a conservative estimate,
if a reasonable estimate of t is available.
Figure 5 displays the time course of absorption of the model
compound, diethyl phthalate,20 presented here to demonstrate
that dermal absorption continues after removal of the load.
Following a 40min exposure (represented by the hashed box on
the time axis) to dermatomed hairless guinea pig skin, the
Figure 4. Model-based data showing how % absorption (a) and total
absorbed amount (b) are modified by the experimental duration for
selected values of Nderm. The dimensionless time number, Ntime, is
the ratio of experimental duration to the lag time for diffusion. For a
given compound, increasing experimental duration increases the
applied load amount that defines a specific Nderm, in accordance
with Eq. (2). Symbols represent calculated values; the lines are a
guide to the eye.
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chemical was removed and the skin was thoroughly rinsed.
Absorption continues for almost three more hours, and over three
times more chemical was absorbed (42 mg/cm2) than had been at
the time the load was removed (13 mg/cm2). The dashed line at
78mg/cm2 represents the total mass absorbed predicted by Eq. (9)
using independently measured kp and t for this non-volatile
compound. Equation (9) overestimates the measured quantity by
about a factor of 2 in this case. Binding of the chemical to skin
components may explain the discrepancy, and Eq. (9) may thus
represent a conservative estimate as there is some question as to
whether this bound fraction is potentially bioavailable.
SUMMARY AND CONCLUSIONS
Finite dose skin permeation experiments serve to model ‘‘real
world’’ exposures and thus provide important information that
can be used in evaluating the risk associated with dermal
exposures. However, care must be taken in analyzing and
interpreting results from such experiments. This manuscript has
described four limitations to the ﬁxed fractional absorption
paradigm. Our analyses of the ﬁrst two pose strategies for
evaluating whether loading effects or evaporation effects might
be expected, and if so they alert to the possibility that the
reported values of fractional absorption require consideration. The
analyses outlined in the case studies are exemplary of strategies to
approach the evaluation of ﬁnite dose absorption data. These
studies suggest an informative strategy for the evaluation of the
dermal absorption potential of a chemical based on careful
assessment of the dermal number, ﬂux number, evaporation
number, time number, and auxiliary equations as presented here.
We propose that an evaluation of ﬁnite dose dermal absorption
data consider the following questions.
Is the Load or Range of Loads Investigated Appropriate?
The fraction or percent of applied dose that is absorbed from ﬁnite
dose experiments depends on the amount of chemical that is
initially loaded onto the skin surface. The dependence is so strong
that it is conceivable that the absorbed amount can range from 0
to 100% for a given chemical. Experimental observations derived
at large Nderm (Eq. (2)) may under represent the fractional
absorption that would be expected at realistic exposures.
Thus, a single, ﬁxed fractional absorption factor may be
inadequate to indicate the true extent of systemic absorption.
Consideration of the dimensionless dermal number Nderm can
guide the risk assessment of ﬁnite dose exposure data. Low values
of Nderm are likely to be representative of exposures that can be
expected in occupational and environmental settings. Therefore,
absorption from experiments at low Nderm can provide important
information regarding the risk for systemic uptake. High values of
Nderm place the experiment in the ﬂux-limited regime, where
excess loading results in low percent absorption that is not
representative of the absorption potential of the applied chemical.
On the other hand, this ﬂux limited, ‘‘inﬁnite dose’’ regime enables
the measurement of steady-state ﬂux, permeability, and lag
time and in our proposed strategy of evaluation its signiﬁcance is
not overlooked.
Does Evaporation Play a Signiﬁcant Role?
For volatile chemicals, the complication of the competing
interplay between absorption and evaporation must be consid-
ered. Evaporation will diminish the applied load such that less
permeant is available for absorption. The dimensionless evapora-
tion number Nevap (Eq. (4)) and related tevap (Eq. (6)) may be used
to evaluate whether load depletion through evaporation is
signiﬁcant. Additionally, the ﬂux number Nﬂux (Eq. (5)) quantiﬁes
the balance between evaporation and absorption, and fractional
or percent absorption may be estimated based on the knowledge
of this parameter using Eq. (7). For highly volatile chemicals, the
percent of applied dose that is absorbed may not achieve a
signiﬁcant level, even for small applied loads. Assessment of
the risk of dermal exposure should then consider the types
of exposures that are likely in the occupational or environmental
setting. Exposures to unoccluded splashes may not lead to
signiﬁcant systemic uptake, but submersion or occluded expo-
sures may contribute to a greater uptake, and thus are better
characterized by considering the maximum ﬂux obtainable for the
given chemical.
Is the Experimental Duration Appropriate?
Dermal absorption from a given load of a permeant with a given
volatility depends on the kinetics of the absorption and
evaporation processes. Therefore, the exposure duration is an
essential consideration in the evaluation of ﬁnite dose exposures.
Exposure duration may be established at the discretion of the
investigator or may be prescribed for regulatory submission but in
either cases it is a signiﬁcant variable in the measured absorption.
The dimensionless time number Ntime (Eq. (8)) can be used to help
evaluate results from ﬁnite dose exposures in terms of evaluating
the impact of experimental duration.
Has the Study Considered the Absorption that Occurs Following
the Exposure time?
We have proposed algebraic expressions to estimate the total
absorption of a non-volatile (Eq. (9)) or volatile (Eq. (10)) chemical
for a given exposure duration or contact time, as long as depletion
of load has not signiﬁcantly limited absorption over the time
course of exposure. These equations may be used in the
evaluation of experiments in which the load is removed after a
given time by washing. The investigator may continue to measure
absorption following removal, or removal may represent the end
point of the experiment. In the latter case, Eqs. (9) and (10) address
the question of whether signiﬁcant absorption may be expected
after the exposure time. As demonstrated in Figure 5, post
exposure absorption can be substantial.
For investigators undertaking ﬁnite dose experiments, the
preceding analysis suggests strategies for the design of experi-
ments that would enhance the utility of the reported results. The
entire absorption proﬁle should be reported, rather than simply
any speciﬁed end point. The kinetics of the absorption process
Figure 5. Time course of in vitro dermal absorption of diethyl
phthalate. Following a 40-min exposure (hashed box on time axis),
the chemical was removed and skin was thoroughly rinsed.
Absorption continues well after the exposure duration. Mass
accumulation at 4 h (42 mg/cm2) was over three times more than
that at 40min (13mg/cm2). Dashed line at 78mg/cm2 represents the
total absorbed amount predicted by Eq. (9).
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provide important information, for example, whether a plateau in
absorption has been reached or if additional absorption would be
expected over additional time. It would also be beneﬁcial if a
range of loads were applied to span a broad range of Nderm. This
provides additional information for evaluating the absorption
potential of the chemical. Although there is an increasing
emphasis on exposure periods and donor conditions that reﬂect
anticipated occupational exposures,36 the role of inﬁnite dose
exposure data remains important. These provide the most reliable
measurements of lag time and steady-state ﬂux, which not only
can be used to predict absorption kinetics from arbitrary loads,
but also provide means of evaluating and interpreting ﬁnite dose
absorption data as outlined herein.
The analysis presented in this paper provides a strategy for
the evaluation of dermal absorption data that acknowledges the
important contribution of ﬁnite dose dermal absorption experi-
ments, and addresses the limitations of a dermal risk assessment
strategy that relies on the single, ﬁxed fractional absorption
paradigm. The application of this strategy should serve to
better characterize the dermal absorption of industrial and
environmental chemicals.
GLOSSARY
Absorption, the process of chemical transport from the outer
surface of skin and into the receptor compartment in an in vitro
experiment, or into the systemic circulation from an in vivo
exposure; Delivery limited, a condition where dermal absorption
is limited by the supply of chemical applied to the surface (dose).
Peak ﬂux will be diminished from its highest value attainable from
a given donor. Compare with ﬂux limited; Dermal absorbed dose,
the total amount of chemical that is absorbed (for in vitro
experiments, mass/area; in an in vivo setting, units are consistent
with exposure units); Donor, the substance applied to the skin
surface. It may consist of a solution or mixture containing the
chemical of interest or the neat (undiluted) chemical; Dose, related
to the amount of chemical applied to skin, dose is used more
loosely than load, and may refer to either an amount (mass/area)
of chemical or a speciﬁed volume of a concentration (mass/
volume) of chemical; Exposure, the mass of chemical in contact
with skin, typically normalized by time (mass/time) and possibly
body mass (mass/mass/time) or exposed area (mass/area/time) of
the organism; Exposure duration, the amount of time the chemical
is in contact with the skin; Experimental duration, the amount of
time that absorption is measured in an experiment. It may be
longer than the exposure duration; Finite dose, a deﬁned, limited
dose; Flux, the rate of mass accumulation per area of exposed
surface (mass/area/time); Flux limited, a condition where dermal
absorption is limited only by the peak steady-state ﬂux attainable
from a given donor. Compare with delivery limited; Fractional
absorption, the fraction of applied dose that is absorbed,
calculated as the dermal absorbed dose divided by the applied
load. It may equivalently be expressed as percent absorption;
Inﬁnite dose, an unlimited dose; in practice one where the applied
dose is minimally depleted through absorption or evaporation;
Lag time, a function of the ﬁnite time it takes for a chemical to
permeate the skin, it is typically calculated as the time-axis
intercept of the asymptote of the steady-state absorption curve
(time); Load, amount of chemical that is in contact with the skin
(mass/area); Maximum ﬂux, the highest ﬂux attainable from a
given chemical, most reliably measured as the slope of the steady-
state absorption curve using an inﬁnite dose of neat chemical;
Peak ﬂux, the highest ﬂux attainable from a given dose; Steady-
state ﬂux, the equilibrium ﬂux that is achieved from an inﬁnite
dose; Systemic uptake, the quantity of chemical that enters the
systemic circulation from a given skin exposure (units are
consistent with exposure units); Vehicle, the solvent or agent
mixed with the target chemical in contact with the skin surface
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APPENDIX
Estimation of Evaporation Flux
The US Environmental Protection Agency24 suggests the use of
the following equation (their Eq. (D-1)) to estimate evaporation
from the surface of a pool of neat liquid, at or near the ambient
temperature, for risk management of chemical spills. It may also
be used to estimate maximum evaporation ﬂux from the donor
compartment of a diffusion cell,25 or from the skin surface in an
in vivo experiment:
Jevap¼ 101; 610 PvapMW
2=3u0:78
T þ 273 ðA1Þ
where Jevap is evaporation ﬂux (mg/cm
2/h), Pvap is the vapor
pressure of the chemical at the ambient temperature (mmHg),
MW is molecular weight, u is wind speed above the liquid surface
(m/s), and T is liquid temperature (1C). Typical values of u for
indoor air range from 0.1 to 0.5m/s.
Vapor pressure depends on temperature. If it is known at one
temperature (T1), it can be estimated at a different temperature
(T2) using a form of the Clausius–Clapeyron equation:
37
ln
Pvap;2
Pvap;1
 
¼ DHvap
R
1
T1þ 273 
1
T2þ 273
 
ðA2Þ
where DHvap is the molar enthalpy of vaporization (J/mol) and R is
the gas constant (8.314 J/mol/K); temperatures T1 and T2 are in 1C.
If no experimental data on vapor pressure are available, a
calculated value may be used, for example, using Episuite.38
In Eq. (A1), Jevap represents the maximum evaporation ﬂux of
the neat chemical. For diffusion cell experiments using diluted
compound, when a chemical is present at a concentration (Cv) less
than the saturation limit in the same vehicle (Sv), the evaporation
ﬂux will be less than the maximum ﬂux by an amount that often is
proportional to the saturation ratio (SR), deﬁned as:
SR¼ Cv
Sv
ðA3Þ
and the evaporation ﬂux under this subsaturated condition may
be estimated:
Jevap;sub¼ JevapSR ðA4Þ
Equations (A3) and (A4) are appropriate for solutions in which
thermodynamic activity is proportional to concentration. Although
this approximation is often a good one, signiﬁcant departures
from this behavior are possible.39
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